- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Verinurad and Allopurinol Combination Lowers SUA Levels but Fails to Improve HFpEF Outcomes, AMETHYST Trial Finds
![Verinurad and Allopurinol Combination Lowers SUA Levels but Fails to Improve HFpEF Outcomes, AMETHYST Trial Finds Verinurad and Allopurinol Combination Lowers SUA Levels but Fails to Improve HFpEF Outcomes, AMETHYST Trial Finds](https://medicaldialogues.in/h-upload/2023/05/22/750x450_210187-heart-failure-1.webp)
USA: In a recent clinical trial, the combination of verinurad and allopurinol demonstrated a notable reduction in serum uric acid (SUA) levels in patients with heart failure with preserved ejection fraction (HFpEF). However, despite this biochemical improvement, the AMETHYST randomized clinical trial found no significant enhancement in key clinical outcomes.
The study, published in JAMA Cardiology, revealed that combining verinurad with allopurinol to lower SUA levels did not improve peak oxygen uptake or symptoms for patients with HFpEF.
"In this randomized clinical trial involving 159 patients, the combination of verinurad and allopurinol led to a significantly greater reduction in SUA levels after 32 weeks than allopurinol alone or placebo. However, this improvement in SUA levels did not translate into significant enhancements in peak oxygen uptake, symptoms, or key echocardiographic parameters in patients with HFpEF and elevated SUA," the researchers reported.
Elevated serum uric acid levels may play a role in endothelial dysfunction, making SUA a promising target for treating heart failure with preserved ejection fraction. However, to date, there have been no randomized clinical trials to assess the effects of SUA reduction specifically in HFpEF patients. To fill this knowledge gap, Dalane W. Kitzman, Wake Forest University School of Medicine, Winston-Salem, North Carolina, and colleagues aimed to investigate the safety and efficacy of the novel urate transporter–1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.
For this purpose, the researchers conducted a phase 2, double-blind, randomized clinical trial from May 2020 to April 2022, involving 59 centers across 12 countries and included patients aged 40 and older with HFpEF and SUA levels greater than 6 mg/dL.
The study, which lasted 32 weeks, randomized eligible participants to receive either once-daily oral verinurad (12 mg) plus allopurinol (300 mg), allopurinol alone (300 mg), or a placebo, following an 8-week titration period. Allopurinol was combined with verinurad to prevent potential urate nephropathy induced by verinurad, and the allopurinol monotherapy group was included to isolate the effects of allopurinol. Additionally, all participants received oral colchicine (0.5 to 0.6 mg) daily for the first 12 weeks.
Data analysis, conducted from August 2022 to May 2024, focused on key outcomes, including changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA levels. The trial also evaluated safety and tolerability, including adjudicated cardiovascular events.
The following were the key findings of the study:
- Among 159 randomized patients (53 per treatment group; median age, 71 years; 65% males) with median (IQR) N-terminal pro-brain natriuretic peptide level of 527 pg/mL and SUA level of 7.5 mg/dL, verinurad plus allopurinol (mean change, −59.6%) lowered SUA level to a greater extent than allopurinol (mean change, −37.6%) or placebo (mean change, 0.8%).
- Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; allopurinol, −0.17 mL/kg/min; placebo, 0.37 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; allopurinol, 4.5; placebo, 1.2) were similar across groups.
- There were no adverse safety signals.
- Deaths or cardiovascular events occurred in 5.7% of patients in the verinurad plus allopurinol group, 15.1% of patients in the allopurinol monotherapy group, and 11.3% in the placebo group.
"The overall results of the AMETHYST randomized clinical trial indicate that lowering SUA levels with verinurad does not lead to improvements in peak VO2 or symptoms for patients with HFpEF," the researchers concluded.
Reference:
Kitzman DW, Voors AA, Mentz RJ, et al. Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial. JAMA Cardiol. Published online August 14, 2024. doi:10.1001/jamacardio.2024.2435
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751